spacer
home > white papers > Financial implications of off-site visits in clinical research, perception versus reality - Illingworth Research
WHITE PAPERS
logo_IllingwortE.jpg

Illingworth Research

phone +44 (0)1625617447
email info@illingworthreseach.com
web http://www.illingworthresearch.com
email Illingworth Research Ltd, Suite 5, Silk House, Park Green, Macclesfield, Cheshire, SK11 7QJ, England

Financial implications of off-site visits in clinical research, perception versus reality

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
Financial implications of off-site visits in clinical research, perception versus reality
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG collaborate on the fast-track manufacturing of a SARS-CoV-2- neutralizing antibody for the therapy of COVID-19

Vilnius, Lithuania, and Schlieren, Switzerland – August 11, 2020 – Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG (MTx), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4-month fast-track process approved by regulatory authorities.
More info >>


White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>


Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement